Spyre (SYRE) CFO sells 12,500 shares under Rule 10b5-1 plan
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
Spyre Therapeutics, Inc. Chief Financial Officer Scott L. Burrows executed a planned option exercise and share sale on Common Stock. On May 1, 2026, he sold 12,500 shares of Common Stock in an open-market transaction at $71.37 per share, pursuant to a Rule 10b5-1 trading plan adopted on November 10, 2025.
The same day, he exercised stock options to acquire 12,500 shares of Common Stock at an exercise price of $14.50 per share. Following these transactions, he directly holds 110,494 shares of Common Stock, which include 67,476 restricted stock units scheduled to vest in two equal installments on September 1, 2026 and September 1, 2027, subject to continued employment. He also retains stock options representing a right to purchase 404,857 shares of Common Stock, vesting over several years.
Positive
- None.
Negative
- None.
Insider Trade Summary 10b5-1
Net Seller: 12,500 shares ($892,125)
Net Sell
3 txns
Insider
Burrows Scott L
Role
Chief Financial Officer
Sold
12,500 shs ($892K)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option (Right to Buy) | 12,500 | $0.00 | -- |
| Exercise | Common Stock | 12,500 | $14.50 | $181K |
| Sale | Common Stock | 12,500 | $71.37 | $892K |
Holdings After Transaction:
Stock Option (Right to Buy) — 382,357 shares (Direct, null);
Common Stock — 110,494 shares (Direct, null)
Footnotes (1)
- This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on November 10, 2025. Includes 67,476 restricted stock units ("RSUs"). Each RSU represents a contingent right to receive, upon vesting, one share of Common Stock. The RSUs vest in two equal installments on each of September 1, 2026 and 2027, subject to the Reporting Person's continued employment with the Issuer. This option represents a right to purchase 404,857 shares of the Issuer's common stock (which have been adjusted to reflect the Issuer's 1-for-25 reverse stock split on September 8, 2023), one quarter of which vested and became exercisable on September 1, 2024, with the remaining three quarters vesting in monthly installments over the following three years, subject to the Reporting Person's continued employment with the Issuer.
Key Figures
Shares sold: 12,500 shares
Sale price: $71.37 per share
Options exercised: 12,500 shares
+5 more
8 metrics
Shares sold
12,500 shares
Common Stock sold on May 1, 2026
Sale price
$71.37 per share
Open-market sale of Common Stock
Options exercised
12,500 shares
Stock options exercised into Common Stock on May 1, 2026
Option exercise price
$14.50 per share
Strike price for exercised stock options
Common shares held
110,494 shares
Direct Common Stock holdings after transactions
RSUs included
67,476 RSUs
Restricted stock units included in Common Stock holdings
Option grant size
404,857 shares
Shares underlying stock option grant
10b5-1 plan adoption date
November 10, 2025
Date trading plan for sale was adopted
Key Terms
Rule 10b5-1 trading plan, restricted stock units ("RSUs"), reverse stock split, Stock Option (Right to Buy)
4 terms
Rule 10b5-1 trading plan financial
"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on November 10, 2025."
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
restricted stock units ("RSUs") financial
"Includes 67,476 restricted stock units ("RSUs"). Each RSU represents a contingent right to receive, upon vesting, one share of Common Stock."
Restricted stock units (RSUs) are a company promise to give an employee shares of stock (or cash equivalent) in the future, but only after certain conditions—usually staying with the company for a set time or hitting performance goals—are met. Investors watch RSUs because when they vest they increase the number of shares outstanding and can lead insiders to sell shares, affecting share price, company dilution and the true cost of employee pay.
reverse stock split financial
"shares of the Issuer's common stock (which have been adjusted to reflect the Issuer's 1-for-25 reverse stock split on September 8, 2023)"
A reverse stock split is when a company reduces the number of its shares outstanding, making each share more valuable. For example, if you own 100 shares worth $1 each, a 1-for-10 reverse split would turn your 100 shares into 10 shares worth $10 each. Companies often do this to boost their stock price and appear more stable to investors.
Stock Option (Right to Buy) financial
"Stock Option (Right to Buy) with an expiration date of September 1, 2033"
FAQ
What insider transactions did Spyre Therapeutics (SYRE) report for its CFO?
Spyre Therapeutics CFO Scott L. Burrows sold 12,500 Common Stock shares at $71.37 and exercised options for 12,500 shares at $14.50 on May 1, 2026, as disclosed in the Form 4 filing.
What are the vesting terms for the Spyre Therapeutics (SYRE) CFO’s RSUs?
The CFO’s 67,476 restricted stock units vest in two equal installments on September 1, 2026 and September 1, 2027. Each RSU converts into one share of Common Stock if he remains employed with Spyre Therapeutics through each vesting date.